Recent Updates
Recently added Catalysts
RVP Neutral Sentiment Score: 45/100

RETRACTABLE TECHNOLOGIES

Key Takeaway: Retractable Technologies, Inc. has officially withdrawn its complaint regarding a 100% tariff on syringes imported from China, which led to the case's dismissal on January 8, 2025. Despite initial concerns regarding improper tariff implementation, RTI management recognized the slim chances of overcoming large corporate interests. In response to challenges, RTI engineers have adapted older equipment to enhance domestic production, aiming to mitigate risks to the company's viability. The focus remains on their innovative medical products designed to prevent needlestick injuries and reduce infection risks.

Market Sentiment Analysis

POSITIVE FACTORS

  • RTI engineers have enhanced the transition process to reduce imports.
  • The company has creatively adapted older equipment for production.
  • Efforts are expected to diminish risks to the company's survival.

CONCERNS & RISKS

  • RTI withdrew its complaint against significant tariffs on imports.
  • Management believes chances of success against large companies are minimal.

Full Press Release Details

RETRACTABLE TECHNOLOGIES, INC. WITHDRAWS
COMPLAINT IN UNITED STATES COURT OF INTERNATIONAL TRADE
LITTLE ELM, TEXAS, January 14, 2025 -
Retractable Technologies, Inc. (NYSE American: RVP) ("RTI" or "Retractable") has withdrawn its complaint
in the United States Court of International Trade against the defendants involved in the issuance of a 100% tariff on syringes and needles
imported from China. As a result, the case was dismissed effective January 8, 2025. Initial investigations into the matter convinced
RTI management that although the tariffs were not properly implemented, there was no chance of RTI being granted additional time to increase
domestic production without tariffs and the chances of a small company prevailing against the interests of a large monopolistic corporation
at this time in history were slim to none.
Meanwhile, RTI engineers have, through creative
adaptation of some of our older equipment, been able to enhance the transition process, which will significantly reduce the need to import
syringes. RTI management expects these efforts to diminish the risks to the continued survival of the company brought about by the recent
Retractable manufactures and markets VanishPoint and
Patient Safe safety medical products and the EasyPoint needle. The VanishPoint syringe,
blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly
from the patient, effectively reducing exposure to the contaminated needle. Patient Safe syringes are uniquely designed
to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint is a retractable
needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint needle
also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general
For more information on Retractable, visit its
Forward-looking statements in this press release
are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current
views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate.
However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from
Factors that could cause or contribute to such
differences include, but are not limited to: material changes in demand, tariffs, Retractable's ability to maintain liquidity; Retractable's
maintenance of patent protection; Retractable's ability to maintain favorable third party manufacturing and supplier arrangements and
relationships; foreign trade risk; Retractable's ability to access the market; production costs; the impact of larger market players in
providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic
reports filed with the U.S. Securities and Exchange Commission.
Retractable Technologies, Inc.
John W. Fort III, 888-806-2626 or 972-294-1010
Vice President, Chief Financial Officer, and Chief

Frequently Asked Questions

Why did Retractable Technologies withdraw its complaint?

Retractable Technologies withdrew its complaint due to low chances of success against larger corporate interests.

What products does Retractable Technologies manufacture?

Retractable produces VanishPoint, Patient Safe safety medical products, and the EasyPoint needle.

When was the complaint officially dismissed?

The complaint was dismissed effective January 8, 2025.

How has RTI adapted to the tariff situation?

RTI has enhanced its equipment to reduce the need for importing syringes.

What is the primary function of EasyPoint needles?

EasyPoint needles can be used for injections, fluid aspiration, and blood collection.

Last updated: Jan 14, 2025